Status:
COMPLETED
Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
Andersen Foundation
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This research is intended to begin to explore the impact of inspiratory muscle resistance exercise and/or 1,25(OH)2D3 for improving respiratory muscle strength in cancer patients (subjects).
Eligibility Criteria
Inclusion
- Diagnosis of cancer
- Renal and hepatic function (creatinine \</= 2 x the institutional upper limit of normal; bilirubin \</= 2 x the institutional upper limit of normal)
- No contraindication to receive either of the planned interventions of inspiratory resistance training or 1,25(OH)2D3 in the opinion of the healthcare provider
- No difficulties with swallowing oral medications in the opinion of the enrolling physician
Exclusion
- Patient is taking calcium or Vitamin D supplements and is unwilling to stop for 8 weeks
- Severe chronic obstructive pulmonary disease (oxygen dependent or patient self-reports unable to walk one block without difficulty)
- Calcium or phosphorus level above the institutional upper limit of normal
Key Trial Info
Start Date :
May 25 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 21 2020
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT03469271
Start Date
May 25 2018
End Date
May 21 2020
Last Update
September 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905